

## Seeking Druggable Targets and Technologies to Monitor Glomerular Filtration Rate in Chronic Kidney Disease and Acute Kidney Injury



Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify druggable targets in Chronic Kidney Disease and Acute Kidney Injury.

### Research Interests

- Chronic Kidney Disease: Mechanisms of action that reduce proteinuria by enhancing podocyte/endothelial integrity, reduce renal inflammation/fibrosis, and/or enhance tissue regeneration
- Acute Kidney Injury: Opportunities associated with clinical stage assets are of high interest
- Acute Kidney Injury: Mechanism of actions improving mitochondrial dysfunction and/or stimulation of regenerative repair, technologies that enable monitoring of real time glomerular filtration rate

### Developmental Stages of Interest

- Research at basic level through to clinical phase II is within scope
- Validation through cell or animal models is encouraged, but research before this stage is also of interest

### Out of Scope

- Agents that act primarily by weight loss or glucose reduction and primarily indicated for diabetes or obesity
- Diabetic Kidney Disease mechanisms of actions that primarily act via changes in hemodynamics or weight loss






### Jurisdictions of Interest

Only submissions from universities and academic institutions in Europe, Africa and the Middle East will be considered.

### Submission Information

Submission of one-page research briefs (approx 200 - 300 words) plus any extra applicable information is encouraged.

#### Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

#### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **25th January 2021 - 11:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)